Volume 8, Issue 1 Supplement, February 2012

Special Issue: Commercial Developments in Purinergic Signalling

ISSN: 1573-9538 (Print) 1573-9546 (Online)

In this issue (9 articles)

  1. Editorial

    Preface to special issue (Commercial Developments in Purinergic Signalling)

    Geoffrey Burnstock Page 1
    Download PDF (44KB) View Article

  2. Original Article

    In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization

    Anthony P. Ford Pages 3-26
    Download PDF (1264KB) View Article

  3. No Access

    Original Article

    Measurement of purine release with microelectrode biosensors

    Nicholas Dale, Bruno G. Frenguelli Pages 27-40
    Look Inside Get Access

  4. No Access

    Original Article

    P2X receptor antagonists for pain management: examination of binding and physicochemical properties

    Rebecca J. Gum, Brian Wakefield, Michael F. Jarvis Pages 41-56
    Look Inside Get Access

  5. No Access

    Orignal Article

    ATPace™: injectable adenosine 5′-triphosphate

    Amir Pelleg, Steven P. Kutalek, Daniel Flammang, David Benditt Pages 57-60
    Look Inside Get Access

  6. Original Article

    Using antibodies against P2Y and P2X receptors in purinergic signaling research

    Dovrat Brass, Melanie R. Grably, Noemi Bronstein-Sitton… Pages 61-79
    Download PDF (1275KB) View Article

  7. No Access

    Original Article

    The impact of commercially available purinergic ligands on purinergic signalling research

    J. R. Flanaghan, S. J. Roome Pages 81-89
    Look Inside Get Access

  8. No Access

    Original Article

    Partial adenosine A1 receptor agonists for cardiovascular therapies

    Barbara E. Albrecht-Küpper, Kirsten Leineweber, Peter G. Nell Pages 91-99
    Look Inside Get Access

  9. No Access

    Original Article

    Development of a comprehensive set of P2 receptor pharmacological research compounds

    R. A. Felix, S. Martin, S. Pinion, D. J. Crawford Pages 101-112
    Look Inside Get Access